Recent Developments in Chemical Synthesis with Biocatalysts in Ionic Liquids
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Technical Information
Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7). -
Separation of the Mixtures of Chiral Compounds by Crystallization
1 Separation of the Mixtures of Chiral Compounds by Crystallization Emese Pálovics2, Ferenc Faigl1,2 and Elemér Fogassy1* 1Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, 2Research Group for Organic Chemical Technology, Hungarian Academy of Sciences, Budapest, Hungary 1. Introduction Reaction of a racemic acid or base with an optically active base or acid gives a pair of diastereomeric salts. Members of this pair exhibit different physicochemical properties (e.g., solubility, melting point, boiling point, adsorbtion, phase distribution) and can be separated owing to these differences. The most important method for the separation of enantiomers is the crystallization. This is the subject of this chapter. Preparation of enantiopure (ee~100%) compounds is one of the most important aims both for industrial practice and research. Actually, the resolution of racemic compounds (1:1 mixture of molecules having mirror-imagine relationship) still remains the most common method for producing pure enantiomers on a large scale. In these cases the enantiomeric mixtures or a sort of their derivatives are separated directly. This separation is based on the fact that the enantiomeric ratio in the crystallized phase differs from the initial composition. In this way, obtaining pure enantiomers requires one or more recrystallizations. (Figure 1). The results of these crystallizations (recrystallizations) of mixtures of chiral compounds differ from those observed at the achiral compounds. Expectedly, not only the stereoisomer in excess can be crystallized, because the mixture of enantiomers (with mirror image relationship) follows the regularities established from binary melting point phase diagrams, and ternary composition solubility diagrams, respectively, as a function of the starting enantiomer proportion. -
II. Stereochemistry 5
B.Sc.(H) Chemistry Semester - II Core Course - III (CC-III) Organic Chemistry - I II. Stereochemistry 5. Physical and Chemical Properties of Stereoisomers Dr. Rajeev Ranjan University Department of Chemistry Dr. Shyama Prasad Mukherjee University, Ranchi 1 Syllabus & Coverage Syllabus II Stereochemistry: Fischer Projection, Newmann and Sawhorse Projection formulae and their interconversions. Geometrical isomerism: cis–trans and syn-anti isomerism, E/Z notations with Cahn Ingold and Prelog (CIP) rules for determining absolute configuration. Optical Isomerism: Optical Activity, Specific Rotation, Chirality/Asymmetry, Enantiomers, Molecules with two or more chiral-centres, Distereoisomers, Meso structures, Racemic mixture. Resolution of Racemic mixtures. Relative and absolute configuration: D/L and R/S designations. Coverage: 1. Types of Isomers : Comparing Structures 2. Optical Activity 3. Racemic Mixtures : Separation of Racemic Mixtures 4. Enantiomeric Excess and Optical Purity 5. Relative and Absolute Configuration 6. Physical and Chemical Properties of Stereoisomers 2 Stereochemistry Types of Isomers Dr. Rajeev Ranjan 3 Stereochemistry Determining the Relationship Between Two Non-Identical Molecules Dr. Rajeev Ranjan 4 Stereochemistry Comparing Structures: Are the structures connected the same? yes no Are they mirror images? Constitutional Isomers yes no Enantiomers Enantiomers Is there a plane of symmetry? All chiral centers will be opposite between them. yes no Meso Diastereomers superimposable Dr. Rajeev Ranjan 5 Stereochemistry Optical Activity: • The chemical and physical properties of two enantiomers are identical except in their interaction with chiral substances. • The physical property that differs is the behavior when subjected to plane-polarized light ( this physical property is often called an optical property). • Plane-polarized (polarized) light is light that has an electric vector that oscillates in a single plane. -
Cross-Linked Protein Crystal Technology in Bioseparation and Biocatalytic Applications
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Aaltodoc Helsinki University of Technology, Department of Chemical Technology Technical Biochemistry Report 1/2004 Espoo 2004 TKK-BE-8 CROSS-LINKED PROTEIN CRYSTAL TECHNOLOGY IN BIOSEPARATION AND BIOCATALYTIC APPLICATIONS Antti Vuolanto Dissertation for the degree of Doctor in Science in Technology to be presented with due permission of the Department of Chemical Technology for public examination and debate in Auditorium KE 2 (Komppa Auditorium) at Helsinki University of Technology (Espoo, Finland) on the 20th of August, 2004, at 12 noon. Helsinki University of Technology Department of Chemical Technology Laboratory of Bioprocess Engineering Teknillinen korkeakoulu Kemian osasto Bioprosessitekniikan laboratorio Distribution: Helsinki University of Technology Laboratory of Bioprocess Engineering P.O. Box 6100 FIN-02015 HUT Tel. +358-9-4512541 Fax. +358-9-462373 E-mail: [email protected] ©Antti Vuolanto ISBN 951-22-7176-1 (printed) ISBN 951-22-7177-X (pdf) ISSN 0359-6621 Espoo 2004 Vuolanto, Antti. Cross-linked protein crystal technology in bioseparation and biocatalytic applications. Espoo 2004, Helsinki University of Technology. Abstract Chemical cross-linking of protein crystals form an insoluble and active protein matrix. Cross-linked protein crystals (CLPCs) have many excellent properties including high volumetric activity and stability. In this thesis CLPC technology was studied in bioseparation and biocatalytic applications. A novel immunoaffinity separation material, cross-linked antibody crystals (CLAC), was developed in this thesis for enantiospecific separation of a chiral drug, finrozole. Previously, the preparation of an antibody Fab fragment ENA5His capable of enantiospecific affinity separation of the chiral drug has been described. -
The Racemate-To-Homochiral Approach to Crystal Engineering Via Chiral Symmetry-Breaking
CrystEngComm The Racemate -to -Homochiral Approach to Crystal Engineering via Chiral Symmetry-Breaking Journal: CrystEngComm Manuscript ID: CE-HIG-02-2015-000402.R1 Article Type: Highlight Date Submitted by the Author: 04-Apr-2015 Complete List of Authors: An, Guanghui; Heilongjiang University, School of Chemistry and Materials Science Yan, Pengfei; Heilongjiang University, School of Chemistry and Materials Science Sun, Jingwen; Heilongjiang University, School of Chemistry and Materials Science Li, Yuxin; School of Chemsitry and Materials Science of Heilongjiang University, Yao, Xu; Heilongjiang University, School of Chemistry and Materials Science Li, Guangming; School of Chemsitry and Materials Science of Heilongjiang University, Page 1 of 12Journal Name CrystEngComm Dynamic Article Links ► Cite this: DOI: 10.1039/c0xx00000x www.rsc.org/xxxxxx ARTICLE TYPE The Racemate-to-Homochiral Approach to Crystal Engineering via Chiral Symmetry-Breaking Guanghui An, a Pengfei Yan, a Jingwen Sun, a Yuxin Li, a Xu Yao, a Guangming Li,* a Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX 5 DOI: 10.1039/b000000x The racemate-to-homochiral approach is to transform or separate the racemic mixture into homo chiral compounds. This protocol, if without an external chiral source, is categorized into chiral symmetry- breaking. The resolution processes without chiral induction are highly important for the investigation on the origin of homochirality in life, pharmaceutical synthesis, chemical industrial and material science. 10 Besides the study on the models and mechanisms to explain the racemate-to-homochiral approach which may give the probable origin of homochirality in life, the recent developments in this field have been plotted towards the separation of enantiomers for the synthesis of pharmaceuticals, chiral chemicals. -
Chapter 4: Stereochemistry Introduction to Stereochemistry
Chapter 4: Stereochemistry Introduction To Stereochemistry Consider two of the compounds we produced while finding all the isomers of C7H16: CH3 CH3 2-methylhexane 3-methylhexane Me Me Me C Me H Bu Bu Me Me 2-methylhexane H H mirror Me rotate Bu Me H 2-methylhexame is superimposable with its mirror image Introduction To Stereochemistry Consider two of the compounds we produced while finding all the isomers of C7H16: CH3 CH3 2-methylhexane 3-methylhexane H C Et Et Me Pr Pr 3-methylhexane Me Me H H mirror Et rotate H Me Pr 2-methylhexame is superimposable with its mirror image Introduction To Stereochemistry Consider two of the compounds we produced while finding all the isomers of C7H16: CH3 CH3 2-methylhexane 3-methylhexane .Compounds that are not superimposable with their mirror image are called chiral (in Greek, chiral means "handed") 3-methylhexane is a chiral molecule. .Compounds that are superimposable with their mirror image are called achiral. 2-methylhexane is an achiral molecule. .An atom (usually carbon) with 4 different substituents is called a stereogenic center or stereocenter. Enantiomers Et Et Pr Pr Me CH3 Me H H 3-methylhexane mirror enantiomers Et Et Pr Pr Me Me Me H H Me H H Two compounds that are non-superimposable mirror images (the two "hands") are called enantiomers. Introduction To Stereochemistry Structural (constitutional) Isomers - Compounds of the same molecular formula with different connectivity (structure, constitution) 2-methylpentane 3-methylpentane Conformational Isomers - Compounds of the same structure that differ in rotation around one or more single bonds Me Me H H H Me H H H H Me H Configurational Isomers or Stereoisomers - Compounds of the same structure that differ in one or more aspects of stereochemistry (how groups are oriented in space - enantiomers or diastereomers) We need a a way to describe the stereochemistry! Me H H Me 3-methylhexane 3-methylhexane The CIP System Revisited 1. -
Prodrugs Design Based on Inter- and Intramolecular Chemical Processes
Chem Biol Drug Des 2013; 82: 643–668 Review Prodrugs Design Based on Inter- and Intramolecular Chemical Processes Rafik Karaman1,2,* compound satisfies a number of preset criteria to start clinical development. The number of years it takes to intro- 1Bioorganic Chemistry Department, Faculty of Pharmacy, duce a drug to the pharmaceutical market is over 10 years Al-Quds University, P.O. Box 20002, Jerusalem, Palestine with a cost of more than $1 billion dollars (1,2). 2Department of Science, University of Basilicata, Via dell’Ateneo Lucano 10, 85100, Potenza, Italy Modifying the absorption, distribution, metabolism, and *Corresponding author: Rafik Karaman, elimination (ADME) properties of an active drug requires a [email protected] complete understanding of the physicochemical and bio- logical behavior of the drug candidate (3 6). This includes This review provides the reader a concise overview of – the majority of prodrug approaches with the emphasis comprehensive evaluation of drug-likeness involving on the modern approaches to prodrug design. The prediction of ADME properties. These predictions can be chemical approach catalyzed by metabolic enzymes attempted at several levels: in vitro–in vivo using data which is considered as widely used among all other obtained from tissue or recombinant material from human approaches to minimize the undesirable drug physico- and preclinical species, and in silico or computational pre- chemical properties is discussed. Part of this review dictions projecting in vitro or in vivo data, involving the will shed light on the use of molecular orbital methods evaluation of various ADME properties, using computa- such as DFT, semiempirical and ab initio for the design tional approaches such as quantitative structure activity of novel prodrugs. -
Preferential Crystallization of a Racemic Compound Via Its Conglomerate Co-Crystals
Preferential crystallization of a racemic compound via its conglomerate co-crystals Master Thesis Oscar F. Villamil R August 24th 2016 Faculty of 3ME Department: Process & Energy Section: Intensified Reaction & Separation Systems Graduation Committee Ir. W. Li PDeng Dr. ir. H.J.M Kramer Dr. ir. H.W.Nugteren Dr. ir. A. van der Heijden 1 Abstract Preferential crystallization, as a powerful chiral resolution technique, is intrinsically limited to chiral molecules that crystallize as conglomerates. Many studies have been conducted on using chemical reactions to convert the target molecules, which originally form racemic compounds, into conglomerate-forming derivatives salts or by creating solvate, for the application of preferential crystallization. Up to this date conglomerate co-crystals of racemic compounds have never been applied as the intermediate for chiral resolution. In this study, preferential crystallization of the model compound Ibuprofen (IBU), originally a racemic compound, was carried out via its conglomerate co-crystal with 2,4-bipyridine ethylene (BPE) in heptane. Suitable operation conditions were selected based on pseudo- binary phase diagram of the model compound system constructed under different IBU-BPE ratio. A unique measurement method combining polarimeter and Nuclear Magnetic Resonance (NMR) measurements was developed to identify the enantiopurity and the yield of the final product, which was a mixture of racemic IBU and IBU-BPE co-crystals, a likely result from this complex system. With respect to the results, preferential crystallization of IBU was successfully performed by slowly cooling down a saturated solution of racemic IBU-BPE, initially at T=57.5°C, after seeding it with S-IBU/BPE crystals to T=53°C with a cooling rate of 0.3°C/min. -
Structure Property Relationships of Carboxylic Acid Isosteres † † † ‡ † Pierrik Lassalas, Bryant Gay, Caroline Lasfargeas, Michael J
Article pubs.acs.org/jmc Structure Property Relationships of Carboxylic Acid Isosteres † † † ‡ † Pierrik Lassalas, Bryant Gay, Caroline Lasfargeas, Michael J. James, Van Tran, † ‡ † § † Krishna G. Vijayendran, Kurt R. Brunden, Marisa C. Kozlowski, Craig J. Thomas, Amos B. Smith, III, † † ‡ Donna M. Huryn,*, and Carlo Ballatore*, , † Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States ‡ Center for Neurodegenerative Disease Research, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States § National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20850, United States *S Supporting Information ABSTRACT: The replacement of a carboxylic acid with a surrogate structure, or (bio)-isostere, is a classical strategy in medicinal chemistry. The general underlying principle is that by maintaining the features of the carboxylic acid critical for biological activity, but appropriately modifying the physico- chemical properties, improved analogs may result. In this context, a systematic assessment of the physicochemical properties of carboxylic acid isosteres would be desirable to enable more informed decisions of potential replacements to be used for analog design. Herein we report the structure− property relationships (SPR) of 35 phenylpropionic acid derivatives, in which the carboxylic acid moiety is replaced with a series of known isosteres. The data set generated provides an assessment of the relative impact on the physicochemical properties that these replacements may have compared to the carboxylic acid analog. As such, this study presents a framework for how to rationally apply isosteric replacements of the carboxylic acid functional group. ■ INTRODUCTION ships (SPR) of the existing palette of isosteres is most desirable. -
Contractor Orientation Manual
Contractor Orientation Manual KALAMAZOO CONTRACTOR ADMINISTRATION TABLE OF CONTENTS INTRODUCTION......................................................................................................................................4 DEFINITIONS...........................................................................................................................................4 1. Supplier: ........................................................................................................................................4 2. Contractor: ………………………………………………………………………………………4 3. Pfizer Contact: ...…………………………………………………………………………….4 4. Kalamazoo Contractor Administration: ……………………………………………………..4 GENERAL INFORMATION....................................................................................................................5 1. Company Access ...........................................................................................................................5 2. Vehicle Admittance & Parking .....................................................................................................5 3. Tobacco Products ..........................................................................................................................6 4. Cafeterias and Snack Bars..............................................................................................................6 5. The Federal Food, Drug and Cosmetic Act................................................................................... 6 6. Good Manufacturing Practices -
Prodrugs: a Challenge for the Drug Development
PharmacologicalReports Copyright©2013 2013,65,1–14 byInstituteofPharmacology ISSN1734-1140 PolishAcademyofSciences Drugsneedtobedesignedwithdeliveryinmind TakeruHiguchi [70] Review Prodrugs:A challengeforthedrugdevelopment JolantaB.Zawilska1,2,JakubWojcieszak2,AgnieszkaB.Olejniczak1 1 InstituteofMedicalBiology,PolishAcademyofSciences,Lodowa106,PL93-232£ódŸ,Poland 2 DepartmentofPharmacodynamics,MedicalUniversityofLodz,Muszyñskiego1,PL90-151£ódŸ,Poland Correspondence: JolantaB.Zawilska,e-mail:[email protected] Abstract: It is estimated that about 10% of the drugs approved worldwide can be classified as prodrugs. Prodrugs, which have no or poor bio- logical activity, are chemically modified versions of a pharmacologically active agent, which must undergo transformation in vivo to release the active drug. They are designed in order to improve the physicochemical, biopharmaceutical and/or pharmacokinetic properties of pharmacologically potent compounds. This article describes the basic functional groups that are amenable to prodrug design, and highlights the major applications of the prodrug strategy, including the ability to improve oral absorption and aqueous solubility, increase lipophilicity, enhance active transport, as well as achieve site-selective delivery. Special emphasis is given to the role of the prodrug concept in the design of new anticancer therapies, including antibody-directed enzyme prodrug therapy (ADEPT) andgene-directedenzymeprodrugtherapy(GDEPT). Keywords: prodrugs,drugs’ metabolism,blood-brainbarrier,ADEPT,GDEPT -
Custom Manufacturing in Thailand, Evonik in China
10/2011 October Markets and Companies Markets and Companies Interview with Styrolution’s CEO THE NEWSPAPER FOR THE Expert Peter Pollak discusses the Roberto Gualdoni CHEMICAL AND fragmented world of fine chemicals Page 5 LIFE SCIENCE MARKE TS Pages 8 and 14 N EWSFLOW Market and Companies: Haltermann sold to H.I.G Europe, Dr. Uwe Nickel named new CEO. An Industry Full of Opportunity DuPont seeking buyers for two se- parate businesses: a polyester-film CPhI Highlights the Latest Trends in Pharma joint venture and one that makes powder-based paint. Bayer and Yunona Holdings have entered a memorandum of under- Markus Blocher Dr. Jörn Winterfeld standing to manufacture drugs in CEO, Dottikon Russia. Director Business Line Pharma/Agro at Wacker Biosolutions, Wacker AstraZeneca has announced it will be laying off about 400 employees in the U.S., primarily at its head- API Fine Chemicals quarters in Wilmington, Del. … Chemical exclusive synthesis partners Consolidation in the fine chemicals industry Lanxess has announced three in- need to possess a versatile technology will continue, since it is a very fragmented vestments totaling upwards of €30 “ portfolio like a Swiss army knife and be as industry. Many small players may vanish million in Brazil. ” “ ” precise and reliable as a Swiss watch. or merge to attain the so-called critical mass. Syngenta has posted a 21 % rise in This trend includes producers in China. its Q3 results over last year. More on Page 2 ▶ Jean Bléhaut Director of Marketing & Business Development, Novasep Dr. Martin Wienkenhöver Under Construction: CEO, CABB Both Solvay and Evonik are building hydrogen peroxide plants; Solvay Custom Manufacturing in Thailand, Evonik in China.